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a b s t r a c t
Despite large investments in drug development, the overall success rate of drugs during clinical
development remains low. One prominent explanation is ﬂawed preclinical research, in which the use
and outcome of animal models is pivotal to bridge the translational gap to the clinic. Therefore, the
selection of a validated and predictive animal model is essential to address the clinical question. In this
review, the current challenges and limitations of animal models are discussed, with a focus on the ﬁt-for-
purpose validation. Moreover, guidance is provided on the selection, design and conduct of an animal
model, including the recommendation of assessing both efﬁcacy and safety endpoints. In order to
improve the clinical translation, the use of humanized mouse models and preclinical applications of
clinical features are discussed. On top, the translational value of animal models could be further
enhanced when combined with emerging alternative translational approaches.
Focal points:
 Bedside
Animal models are essential for translation of drug ﬁndings from bench to bedside. Hence, critical
evaluation of the face and predictive validity of these models is important. Reversely, clinical bedside
ﬁndings that were not predicted by animal testing should be back translated and used to reﬁne the
animal models.
 Benchside
Proper design, execution and reporting of animal model results help to make preclinical data more
reproducible and translatable to the clinic.
 Industry
Design of an animal model strategy is part of the translational plan rather than (a) single experiment
(s). Data from animal models are essential in predicting the clinical outcome for a speciﬁc drug in
development.
 Community
Review, standardization and reﬁnement of animal models by disease expert groups helps to improve
rigor of animal model testing. It is important that the applied animal models are validated ﬁt-for-
purpose according to stringent criteria and reproducible.
 Governments
As during drug development ﬁt-for-purpose animal models are key for success in clinical translation,
ﬁnancial investments and support from the government to develop, optimize, validate and run such
translation tools are important. Over time, this will be of beneﬁt for patients and healthcare
institutions.
 Regulatory agencies
Preclinical testing of a drug in an animal model is not a prerequisite for regulatory agencies before
entering clinical trials, but does unquestionably provide valuable data on the expected clinical
performance of the drug. Hence, testing in animal models is largely recommended from both a
business and patient perspective. In addition, inclusion of safety parameters in animal models will
help to build the required safety data package of drugs in development.
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1. Introduction
Success rates for drugs during clinical development remain low
despite the human genome project and other molecular biology
approaches having identiﬁed a large number of potential new drug
targets. Moreover, progress in the design of small molecule drugs
(e.g. computer aided drug design) and the development of new
biological drug formats such as Nanobodiess [1], has yielded a
plethora of promising drug candidates addressing these potential
new targets. As a consequence, a higher number of drugs interact-
ing with less validated targets have entered clinical development
during the last decade. However, this had led to a decline in the
success rates for drugs during clinical development. The main
reason for these failures is the lack of efﬁcacy during phases II
and III of clinical development [2,3]. The possible failure rates could
be decreased by having more stringent success criteria during the
non-clinical stages of the drug development process. This is
especially true during target validation and the preclinical proof
of concept stage for a given development candidate. Success during
these stages is heavily dependent on the selected animal models
that allow for assessment of the target validity, and that can predict
clinical efﬁcacy of a speciﬁc compound. A model is a simple
representation of a complex system. Consequently, an animal model
for a human disease is by no means attempting to reproduce the
human disease with all its complexities in an animal but rather to
model speciﬁc aspects of a disease. Whenever using an animal
model, it is thus of utmost importance to deﬁne a speciﬁc question
and to ensure that the chosen model is ﬁt-for-purpose.
When adequately designed and conducted, animal models can
contribute invaluable information to our knowledge of biology and
medicine, including the discovery and development of new drugs.
However, better design and conduct as well as further development
of animal models is warranted. The current paper highlights some
aspects for improving the translational value of animal models.
2. Proper design, conduct and reporting of experiments
The best validated animal model (for validation criteria see
further below) is not able to yield conclusive data when the
experimental design is ﬂawed or the execution of the study is
not well controlled. A number of factors which should be con-
sidered in conducting animal studies and that are well-known
though not always followed are highlighted below:
(1) Time course of treatment: In animal models, treatment is fre-
quently initiated either before or shortly after the disease pathol-
ogy is initiated, i.e. before or early during the course of the disease
(prophylactic treatment). This is in contrast to the clinical situation
in which treatment is normally started after onset of symptoms
and clear diagnosis (therapeutic treatment). Thus, a potential
pharmacological effect could be overestimated in an animal
model, simply because therapeutic intervention occurs earlier in
the disease process as compared to the clinical situation.
(2) Animal characteristics and background: The species and strain
of animals selected for a particular model need to be carefully
selected. First of all, the drug to be tested should be fully cross
reactive to the animal target. This is especially an issue for
many biological drugs that are often cross reactive to non-
human primates only. In addition, the age, gender and health
status of the animals should be matched as closely as possible
to the clinical condition. Malignancies, Alzheimer's disease or
osteoarthritis are diseases of the elderly population and thus
screening of new drug candidates in young animals can give
misleading results [4]. Finally, depending on the pathology and
the target of interest, very special conditions in the design
need to be considered. The anti T-cell co-stimulatory receptor
CD28 antibody TGN1412 caused a severe cytokine storm in its
ﬁrst human volunteer trial [5,6], an effect that was not
observed in animal models using non-human primates. One
potential reason that might have contributed to this discre-
pancy is the fact that the antibody caused the activation of
memory T-cells in the human volunteers, but less so in non-
human primates despite a near 100% sequence identity of the
target [7].
(3) Subjective endpoints: Many outcomes used in animal models
are dependent upon subjective interpretation. While subjec-
tive evaluations are generally a very efﬁcient way to score
behavioral endpoints, it can create bias if the scorer is aware of
the animal's treatment. Thus, ideally the experimenter should
be unaware of the treatments or manipulations of the animals
he is dealing with. In addition, the intra- and inter-operator
variation of most subjective measures is high, and standardi-
zation is difﬁcult.
(4) Reproducibility of experimental animal results: While most
experimental set-ups are very much standardized in a particular
lab, slightly different parameters in another one may yield
different results [8–10]. Repetition of experimental ﬁndings in
slightly different models (e.g. a tumor xenograft model with a
different cell line of the same cancer type) might thus help to
ensure the observed effect is generalizable to a broader context.
(5) Group size: For ethical and other reasons, the number of animals
used for biomedical experiments is minimized. However, this
needs to be balanced with the statistical power required to
generate solid data in order to either verify, or to reject the
experimental hypothesis.
(6) Reporting: recent review articles have addressed the issue of
insufﬁcient reporting of experimental animal data which
makes it difﬁcult for others to reproduce those experiments
[11–14]. Thus, for this question, the reader is referred to the
published reviews. An additional problem is that experiments
with a positive outcome are more likely to be published than
negative results.
3. Implementing safety
During the evaluation of a drug candidate, the assessment of
efﬁcacy and safety is normally performed in different experiments,
with a possible overlap in some doses. While efﬁcacy is usually
assessed in disease models without monitoring of side effects,
safety is examined in healthy animals at high dose. The doses
effective in the disease model are then compared to that in the
safety evaluation to yield a safety margin. This margin might be
systematically overestimated for two reasons:
(1) Healthy animals normally used for the safety assessment
might be less sensitive for potential side effects as compared
to diseased subjects.
(2) The efﬁcacy in a disease model could be overestimated when
disregarding potential side effects making it impossible to
administer corresponding doses in a clinical setting. Moreover,
they could directly interfere with correct interpretation of end-
points. For instance, many drugs at high doses could have
unspeciﬁc effects on motor activity while many behavioral
efﬁcacy parameters are directly or indirectly depending on a
motor response. Any unspeciﬁc effect of a drug on motor activity
can therefore be falsely interpreted as a false positive effect.
The risk for this possible efﬁcacy overestimation could be
mitigated by using animal disease models for assessing the safety
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of drugs in parallel with the standard safety testing. For instance,
animals suffering from chronic epilepsy have been shown to be
more susceptible than healthy animals to cognitive impairing side
effects of the anticonvulsant drug valproate [15]. Consequently,
including safety and quality of life endpoints (e.g. overall activity,
body weight, food consumption) in animal efﬁcacy studies should
become standard.
4. Validation of an animal model and a preclinical strategy
Animal models can be validated according to a number of
different criteria:
(1) Face validity: The similarity in biology and symptoms between
the animal model and the human disease. Although important
for the validation of a disease model, assessing face validity is
often hampered by lack of understanding the biology under-
lying the disease symptoms.
(2) Predictive validity: Demonstration that clinically effective inter-
ventions demonstrate a similar effect in the model. This is often
difﬁcult to achieve given incomplete correlation between animal
and human disease mechanisms, and the inability of approved
human drugs to be active in the appropriate animal model species.
(3) Target validity: The target under investigation should have a
similar role in the disease model as in the clinical situation.
One classical example is the beta-3 adrenergic receptor which
has an important role in the energy metabolism of rodents but
not in humans [16].
These criteria are typically used to provide a general validation
of a model. However, since animal models can be used for quite a
variety of different purposes (e.g. examining pathomechanisms,
benchmarking compounds against standard of care, providing
proof of concept for a new target), it is important that the
validation provided for a given model is ﬁt-for-purpose. For
instance, face validity may be more important when researching
potential pathomechanisms whereas the predictive validity has a
higher priority for models to be used for benchmarking.
A model, by deﬁnition, is not a perfect replication of the clinical
condition. Thus, not all criteria can be met by a single model.
However, a combination of different models can eventually come
closer to the clinical situation than a single, even highly sophisti-
cated model. In an attempt to deﬁne an optimal combination of
models, Sams-Dodd [17] has proposed a model validity scoring
system which, in an extended version, is shown in Table 1.
This scoring system uses ﬁve different criteria:
(1) Species: The closer a species comes to human, the more likely it
is that the pathophysiology of the disease is similar to humans.
(2) Complexity: The more complex the test system is, the more
probable that the relevant mechanisms are included. For
instance, an in vitro ion-channel test may detect the effect of
a test compound on conductance of a cardiac ion-channel
whereas an ex vivo or an in vivo test system can evaluate its
effect on the overall cardiac effect e.g. on contractibility.
(3) Disease simulation: Current models use different principles to
induce the disease of interest. The simplest models do not
even attempt to induce a disease but simply look at a measure
in healthy individuals, e.g. the use of memory to predict
cognitive enhancing effects of drug candidates to treat Alzhei-
mer's disease. Somewhat more complex is the use of drugs to
induce disease symptoms such as phencyclidine or ampheta-
mine to elicit psychotic like symptoms. For many disorders the
etiology has not been fully elucidated making it nearly
impossible to truly simulate the disease in a model. Infectious
diseases may be one of the exceptions on the ease of replicat-
ing a disease simulation as shown for example by the devel-
opment of a sophisticated neonatal lamb model for respiratory
syncytial virus (RSV) infection [18].
(4) Predictivity: A drug effect in an experimental model can, in
principle, be observed in two different manners: a quantal or a
graded response. A quantal response does just indicate as to
whether a drug is active or not. A graded response, however,
allows one to distinguish between drugs or doses with higher
and lower activity. Such models allow the comparison of
different drugs and may help to decide as to whether an
experimental compound has a similar or even superior efﬁcacy
to the existing standard of care.
(5) Face validity: This criterion can be further differentiated
depending on whether just one symptom of a disease is
modeled or a set of symptoms and whether this includes core
symptoms as for instance deﬁned in the ICD-10 (www.who.int).
This scoring system can help to assemble a screening cascade/
combination of models which altogether has maximal validity. For
example, the neonatal lamb model for RSV infection scores high
for all criteria other than species and could thus be ideally
complemented by an ex vivo human cell culture model [19].
5. Humanization of models
Humanized mouse models in which immunodeﬁcient mice are
engrafted with human cells or tissues, are considered extremely
useful as they permit functional research studies in vivo and hence
support clinical translation. Dependent on the human disease and
question addressed, different humanized models and mouse
strains are utilized [20]. Most commonly used are the human
tumor xenograft models for study of cancer, and the humanized
mouse models that mimic the human immune system.
5.1. Human tumor models (e.g. PDX)
Many preclinical animal models in oncology drug development fail
to accurately predict the clinical efﬁcacy of novel anticancer agents,
Table 1
Proposed validity scoring system. Adapted from [17].
Criterion Value Score
Species Human 4
Non-human primate 3
Non-human mammal 2
Non-mammal 1
Disease simulation True 4
Complex 3
Pharmacological 2
No 1
Face validity 41 core symptom 4
1 core symptom 3
1 symptom 2
No 1
Complexity In vivo 4
Tissue 3
Cellular 2
Sub-cellular/molecular 1
Predictivity Graded for all pharmacology principles 4
Graded for certain pharmacology principles 3
All or none for certain pharmacology principles 2
No or not shown 1
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largely due to their inability to reﬂect the complexity and hetero-
geneity of human tumors. Patient-derived xenograft (PDX) models,
where surgically resected primary tumor samples are engrafted
directly from patients onto immunodeﬁcient mice, maintain more of
the molecular, genetic and histological heterogeneity of their parental
tumors [21]. The possible advantages of PDX models compared to
other preclinical alternatives in oncology are listed in Table 2. Well
characterized PDX models represent an information-rich preclinical
resource for analysis of drug activity, including novel drug combina-
tions, as well as predictive biomarker discovery [22,23]. PDX models
can be predictive for efﬁcacy of cytotoxic drugs in patients, when these
chemotherapeutics are tested in mice using pharmacokinetically
clinically equivalent drug doses [24,25], and they offer a route towards
personalized medicine for cancer patients. As a proof of principle for
the latter, tumor graft models developed for sarcoma, melanoma,
adenocarcinoma [26] and ovarian cancer [27] demonstrated strong
correlation with clinical efﬁcacy when tumor graft response was used
to guide treatment for patients. Although all these examples highlight
the potential for these PDX models to become the standard for
modeling human cancers, there are still a number of disadvantages
related to the use of PDX models (Table 2).
5.2. Mice with humanized immune system
Over the last decade, much progress has been achieved in the
development of appropriate humanized mouse models to serve
preclinical translational research of the human immune system
in vivo. Following discovery of the ﬁrst immunodeﬁcient strains (nude
and SCID mice), various series of new strains have been generated
[20]. Fig. 1 presents a simpliﬁed overview of the development of
various immonodeﬁcient mice for humanized mouse models.
A remarkable improvement was obtained by introducing the mutated
IL-2 receptor gamma chain (IL-2Ry) into the parent NOD/SCID and
RAG1/2-/- immunodeﬁcient mouse strains [28,29]. These strains fea-
ture multiple immunodeﬁciencies, including defects in T-, B- and
natural killer cells, reduced macrophage and dendritic cell function.
After transplantation of human hematopoietic stem cells (HSCs), these
mice develop well-differentiated multi-lineage hematopoietic cells.
For instance, T-cell subpopulations including CD4þ and CD8þ cells
develop in these mice, while they are not differentiated in the earlier
generation NOD/SCID immunodeﬁcient mice. Further improvement in
recapitulating the bona ﬁde human immune system was achieved by
introducing human genes for various cytokines (e.g. IL-2, IL-4, IL-6,
GM-CSF) or HLA class I and II [30,31]. The engrafted functional human
immune systems are capable of T- and B-cell dependent immune
responses, antibody production, anti-viral responses, and allograft
rejection. Applications of these mouse models with a reconstituted
human immune system are various, and include the investigation of
cancer immunotherapy, regenerative medicine, human stem cell
transplantation and vaccines. For instance, HIV-infected humanized
mice are used to evaluate new therapies regulating chronic immune
activation and replication of HIV [32]. Another example of the use of
humanized mouse models is the preclinical cancer research with
novel drug candidates such as chimeric antigen receptors (CARs) [33].
6. Introducing clinical trial features
The translational gap between animal models and clinical trials
can be bridged by making animal model testing more clinical
trial like.
6.1. Important clinical endpoints are not established or not
assessable in animal models
Quality of life is an important endpoint in clinical trials for a variety
of different chronic diseases, mostly to support reimbursement. This
clinical evaluation is most often assessed by questionnaires, a meth-
odology that obviously cannot be used in experimental animals.
However, there are recent attempts in animals to model pain ques-
tionnaires which serve as primary outcome measures in clinical trials.
Table 2
Advantages and disadvantages of PDX compared to other preclinical oncology models. Adapted from [21,41,42].
Model Advantages Disadvantages
Syngeneic mouse tumor models,
including genetically engineered
mice (GEMs)
– Possibility to model tumor development and premalignant
neoplastic stages
– Tumor heterogeneity exists with multiple lesions in
one mouse
– Tumor microenvironment (stroma and immune system) is
representative of the studied tumor
– Studies on deﬁned mutations possible, including the analysis
of the effects of these mutations in many genetic backgrounds
– Target tissue expression pattern can be different between
mouse and human
– Tumor and microenvironment are both murine and
human/mouse cross-reactive compounds are required
– Tumor development in animals slow and variable
– Development costly and time consuming
– Limited number of genes can be engineered
Human tumor cell derived xenograft
on immunodeﬁcient mice
– Allows a rapid analysis of response to a therapeutic regimen
– Source of material virtually unlimited for immortal cell lines
– Immunodeﬁcient mice cannot adequately capture the
intact human immune component
– Human tumor microenvironment is not represented
– Orthotopic implant is often technically complicated
– In vitro passages induce artiﬁcial drift leading to
outgrowth of cells with different characteristics than
primary tumors
– Poor predictive value
Patient-derived xenograft (PDX) on
immunodeﬁcient mice
– No evolutionary selection pressure from in vitro culture
assuring a realistic reﬂection of original tumor heterogeneity
– Stromal component is representative of the parental tumor in
the initial passages
– One tumor model¼one patient
– Offer the opportunity to evaluate tumors from metastatic sites
or tumors that have developed resistance to multiple
treatments
– Studies have shown very good correlation between response
in PDX models and clinical response in patients
– Immunodeﬁcient mice cannot adequately capture the
intact human immune component
– Tumor development in animals is slow (tumor graft
latency from 2 to 12 months)
– Low engraftment rates for some tumor types (varying
from 23–75%) and only a limited source of original
material
– Orthotopic implant is often technically complicated
– Expensive and labor intensive to establish and maintain
PDX bank
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For instance, the human brief pain inventory was successfully modeled
in dogs suffering from cancer pain [34].
6.2. Animal models use other endpoints than the preferred endpoints
in clinical trials
Disease models are often designed to give a readout that is
easily measureable, objective and gives a large window between
healthy and diseased subjects. While this makes the experimental
design of the animal study more robust and reproducible, this may
not always be the endpoints requested from regulatory authorities
for pivotal clinical trials. In preclinical tumor models for instance
the tumor size is often the primary endpoint, while overall
survival is commonly used in oncology clinical trials. The latter
does not necessarily need to be directly dependent upon tumor
mass. For ethical reasons, survival is rarely an acceptable endpoint
in experimental animals. Progression free survival which often is a
secondary endpoint in clinical studies could, however, be included
in preclinical models.
6.3. Predictive biomarker discovery in animal models
An integrated preclinical approach using PDX models together
with systems biology can for instance enable the discovery and
development of predictive biomarkers for classifying clinical
tumor responsiveness to novel agents [22,23]. More speciﬁcally,
a novel targeted therapy can be screened in a cohort of tumor-
speciﬁc PDX models to determine efﬁcacy, using a sensitive
(regression) versus resistant (progression) classiﬁcation system.
Multiple layers of ‘omics’ technologies (e.g. genome sequencing,
transcriptome proﬁling, proteomics, metabolomics) can then
be employed to characterize these PDX models to derive an
“integrative classiﬁer” to predict sensitive and resistant models
in response to the drug. If the assay development seems feasible,
this classiﬁer or predictive biomarker could be submitted to
preclinical validation by correct prediction of efﬁcacy in an
independent cohort of PDX models. If the classiﬁer achieved a
high level of accuracy in this experiment, biomarker-driven
clinical trials could be designed based on the prevalence of the
identiﬁed biomarkers and their link with efﬁcacy.
6.4. Back translation from clinical trials to animal models
Clinical success also represents lessons learnt for preclinical
research. Hence, it is important to feed back the clinical data to
further improve and ﬁne tune the predictive value of the next
generation of drugs as guided by biomarkers. Proteomics are
emerging biomarkers in preclinical and clinical research, a process
in which the translation and back translation is crucial in order to
improve the patient outcomes [35]. Alternatively, in case of clinical
failure, back translational research in animal models might sup-
port the understanding of the clinical data and mode of action
of drug.
7. Future perspectives
During the last decades, investment in development of new
technologies and reﬁnement of existing technologies has been
considerably higher in areas such as molecular biology or clinical
trial biomarkers than it has been in development of more
predictive animal models. Exceptions are the areas outlined above
e.g. the development of humanized experimental animals. As a
consequence, animal modeling is more and more debated and few
improvements have been implemented during the last two dec-
ades. Improving the quality of animal models involves three
Fig. 1. A simpliﬁed schematic overview of the historical development of various immonodeﬁcient mice for humanized mouse models. Adapted from [20].
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things: improving the performance quality of existing models
(e.g. proper design and execution of experiments), improving the
way in which animal models are used in the decision making
process and investing in the development of more sophisticated
and clinical relevant and predictive models.
Several alternatives for animal model testing have been pro-
posed. One of those potential alternatives is the use of experi-
mental clinical trials, e.g. in which disease is modeled in healthy
subjects, which allow the early clinical testing of drug candidates
without prior extensive animal model testing. Following a number
of failures in clinical development of analgesic drugs, experimental
clinical pain protocols have been developed for providing early
clinical proof of concept within the boundaries of a phase I clinical
trial design [36,37]. While these human models have helped to
bridge the translational gap, they constitute rather an addition in
the translational research armamentarium than a substitute for
well-designed animal models. Their major advantage (i.e. invol-
ving human subjects) should be balanced with the often simplistic
design of experimental clinical trials. A more recent approach is in
silico modeling or also called quantitative systems pharmacology
[38–40]. By modeling disease mechanisms, the efﬁcacy of
drugs addressing known or novel targets on clinical endpoints
and biomarkers is predicted. Ideally, quantitative systems phar-
macology is combined with disease models in a way that certain
speciﬁc hypothesis are generated that can subsequently be
assessed in experimental animals and ﬁnally be fed back into the
in silico model to potentially reﬁne the hypothesis. Thus these
approaches are rather an addition to than a substitution of animal
models.
In summary, animal models when carefully selected, designed
and conducted are an important part of any translational drug
development strategy. Their translational value can be further
enhanced when combined with other translational tools such as
quantitative systems pharmacology, biomarkers or experimental
clinical trials.
Executive summary
 Animal models are essential to bridge the translational gap
between preclinical and clinical research.
 More appropriate preclinical testing in ﬁt-for-purpose animal
models might result in increased clinical success rates for drugs
in development.
 Fit-for-purpose validation of an animal model takes into
account the speciﬁc objectives to be addressed by the model.
 Humanization of animal models has helped to improve the
clinical translation, especially in oncology and inﬂammatory
diseases.
 The translational value of animal experiments can be enhanced
by the inclusion of safety parameters and more clinically
relevant endpoints.
 Design of a translational strategy including systems pharma-
cology and exploratory clinical trials is preferred over the focus
on isolated animal experiments.
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